Christie NHS Foundation Trust

Hospital


Location: Manchester, United Kingdom (GB) GB

ISNI: 0000000404309259

ROR: https://ror.org/03v9efr22

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial (2022) Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, et al. Journal article Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach (2022) Mauri D, Kamposioras K, Matthaios D, Tolia M, Nixon I, Dambrosio M, Zarkavelis G, et al. Journal article, Review article Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) (2022) Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, et al. Journal article The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients (2022) Cives M, Hernando J, Lamarca A, Bouvier C, Caplin M, Pavel ME Journal article Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party (2021) Hayden PJ, Eikema DJ, De Wreede LC, Koster L, Kroger N, Einsele H, Minnema M, et al. Journal article RESULTS OF THE IELSG32 TRIAL AT A MEDIAN FOLLOW-UP OF 88 MONTHS DEMONSTRATE THAT MATRIX FOLLOWED BY AUTOLOGOUS TRANSPLANT IS ASSOCIATED WITH EXCELLENT SURVIVAL AND NEUROTOLERABILITY IN PATIENTS WITH PRIMARY CNS LYMPHOMA (2021) Calimeri T, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Steffanoni S, Foppoli M, et al. Conference contribution Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability (2021) Dromain C, Sundin A, Najran P, Vidal Trueba H, Dioguardi Burgio M, Crona J, Opalinska M, et al. Journal article Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours (2021) Dawod M, Gordoa TA, Cives M, De Mestier L, Crona J, Spada F, Oberg K, et al. Journal article, Review article Advanced small intestine well-differentiated neuroendocrine tumors (WD-SiNET): A survey of practice on 3rd line treatment (2021) Lamarca A, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel ME, Alonso-Gordoa T Conference contribution Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) Rogiers A, Da Silva IP, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, et al. Journal article
1 2 3 4 5